Skip to main content
. 2021 Jul 19;19(1):14–22. doi: 10.1038/s41423-021-00734-4

Table 1.

Developments in CD40-associated agonism

Format Example Ref
CD40L Multimerization [81, 82]
Signaling domain in CAR-T [24]
Expressed by cellular therapy [74]
Expressed by virus [79, 94, 97]
Agonistic anti-CD40 FcR modification [96]
Epitope selection [85]
Bispecific recombinants [90, 91]